Residual inflammation and viral reservoirs: Alliance against an HIV cure

Current Opinion in HIV and AIDS

Volumn 11, Issue 2, 2016, Pages 234-241

  Massanella, Marta ^a,b   Fromentin, Rémi ^a,b   Chomont, Nicolas ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

HIV reservoir; immune activation; immune checkpoint blockers; proliferation

Indexed keywords

CYCLOSPORIN; DIDEHYDROCORTISTATIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; LOSARTAN; RAPAMYCIN; RUXOLITINIB; TELMISARTAN; TOFACITINIB; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE REGULATION; CELL PROLIFERATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MICROENVIRONMENT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS GENOME; VIRUS REPLICATION; VIRUS TRANSCRIPTION; VIRUS TRANSMISSION; DRUG EFFECTS; HIV INFECTIONS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; VIROLOGY; VIRUS LATENCY;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATION; VIRUS LATENCY;

EID: 84957427579     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000230     Document Type: Review

References (102)

1. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-1300.
2. Wong JK, Hezareh M, Günthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-1295.
3. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94: 13193-13197.
4. Fletcher CV, Staskus K, Wietgrefe SW, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci 2014; 111: 2307-2312.
5. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9: 727-728.
6. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15: 893-900.
7. Hatano H, Jain V, Hunt PW, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis 2013; 208: 50-56.
8. Cockerham LR, Siliciano JD, Sinclair E, et al. CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells. Plos One 2014; 9: e110731.
9. Chun T-W, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 2007; 195: 1762-1764.
10. Sigal A, Baltimore D. As good as it gets? The problem of HIV persistence despite antiretroviral drugs. Cell Host Microbe 2012; 12: 132-138.
11. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16: 460-465.
12. Yukl SA, Shergill AK, Mcquaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS (London, England) 2010; 24: 2451-2460.
13. Chun T-W, Nickle DC, Justement JS, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005; 115: 3250-3255.
14. Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010; 202: 1553-1561.
15. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200: 749-759.
16. Deleage C, Moreau M, Rioux-Leclercq N, et al. Human immunodeficiency virus infects human seminal vesicles in vitro and in vivo. Am J Pathol 2011; 179: 2397-2408.
17. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355-358.
18. North TW, Higgins J, Deere JD, et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 2010; 84: 2913-2922.
19. Sheth PM, Chege D, Shin LYY, et al. Immune reconstitution in the sigmoid colon after long-term HIV therapy. Mucosal Immunol 2008; 1: 382-388.
20. Chun T-W, Nickle DC, Justement JS, et al. Persistence of HIV in gutassociated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197: 714-720.
21. Rothenberger MK, Keele BF, Wietgrefe SW, et al. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc Nat Acad Sci 2015; 112: E1126-E1134.
22. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-294.
23. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Antivir Ther (Lond) 2011; 16: 1139-1147.
24. Thompson CG, Bokhart MT, Sykes C, et al. Mass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirs. Antimicrob Agents Chemother 2015; 59: 2944-2948.
25. Sigal A, Kim JT, Balazs AB, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477: 95-98.
26. Biancotto A, Iglehart SJ, Vanpouille C, et al. HIV-1 induced activation of CD4+ T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. Blood 2008; 111: 699-704.
27. Doitsh G, Cavrois M, Lassen KG, et al. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 2010; 143: 789-801.
28. Doitsh G, Galloway NLK, Geng X, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 2014; 505: 509-514.
29. Monroe KM, Yang Z, Johnson JR, et al. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science 2014; 343: 428-432.
30. Schacker TW, Nguyen PL, Beilman GJ, et al. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002; 110: 1133-1139.
31. Schacker TW, Brenchley JM, Beilman GJ, et al. Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4+ T cells in human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2006; 13: 556-560.
32. Zeng M, Smith AJ, Wietgrefe SW, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011; 121: 998-1008.
33. Lindqvist M, van Lunzen J, Soghoian DZ, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest 2012; 122: 3271-3280.
34. Petrovas C, Yamamoto T, Gerner MY, et al. CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest 2012; 122: 3281-3294.
35. Hong JJ, Amancha PK, Rogers K, Ansari AA, Villinger F. Spatial alterations between CD4+ T follicular helper, B, and CD8+ T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. J Immunol 2012; 188: 3247-3256.
36. Connick E, Mattila T, Folkvord JM, et al. CTL fail to accumulate at sites of HIV- 1 replication in lymphoid tissue. J Immunol 2007; 178: 6975-6983.
37. Perreau M, Savoye A-L, De Crignis E, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013; 210: 143-156.
38. Xu GJ, Kula T, Xu Q, et al. Comprehensive serological profiling of human populations using a synthetic human virome. Science 2015; 348: aaa0698-aaa0698.
39. Folkvord JM, Armon C, Connick E. Lymphoid follicles are sites of heightened human immunodeficiency virus type 1 (HIV-1) replication and reduced antiretroviral effector mechanisms. AIDS Res Hum Retroviruses 2005; 21: 363-370.
40. Fukazawa Y, Lum R, Okoye AA, et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med 2015; 21: 132-139.
41. Llibre JM, Buzon MJ, Massanella M, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther (Lond) 2012; 17: 355-364.
42. Massanella M, Esteve A, Buzon MJ, et al. Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification. J Acquir Immune Defic Syndr 2013; 63: 152-160.
43. Hatano H, Strain MC, Scherzer R, et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis 2013; 208: 1436-1442.
44. Vallejo A, Gutié rrez C, Hernández-Novoa B, et al. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 2012; 26: 1885-1894.
45. Gandhi RT, Coombs RW, Chan ES, et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 59: 229-235.
46. Gandhi RT, Bosch RJ, Aga E, et al. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis 2010; 201: 293-296.
47. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7: ; pii: e1000321. doi: 10.1371/journal.pmed.1000321.
48. Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011; 203: 960-968.
49. Massanella M, Negredo E, Puig J, et al. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. AIDS 2012; 26: 2285-2293.
50. Negredo E, Massanella M, Puertas MC, et al. Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. J Antimicrob Chemother 2013; 68: 2358-2362.
51. Lichtenstein KA, Armon C, Nagabhushanam V, et al. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses. Antivir Ther (Lond) 2012; 17: 1301-1309.
52. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197: 126-133.
53. Hatano H, Yukl SA, Ferre AL, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog 2013; 9: e1003691.
54. Hunt PW, Shulman NS, Hayes TL, et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood 2013; 121: 4635-4646.
55. Gutié rrez C, Díaz L, Vallejo A, et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. Plos One 2011; 6: e27864.
56. Beliakova-Bethell N, Jain S, Woelk CH, et al. Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression. Antiviral Res 2014; 107: 42-49.
57. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014; 370: 901-910.
58. Zeidan J, Lee G, Fourati S, et al. Decay of the HIV reservoir post autologous transfer of ZFN CCR5 modified CD4 T cells (SB-728-T) correlates with generation of a T memory stem cell-like population and enhanced HIVspecific CD8 T cell polyfunctionality. Keystone Symposia Mechanisms HIV Persistence: Implications for a Cure 2015; Boston, USA.
59. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008; 112: 2826-2835.
60. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. NatMed 2006; 12: 1365-1371.
61. Chege D, Sheth PM, Kain T, et al. Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS (London, England) 2011; 25: 741-749.
62. Kim CJ, McKinnon LR, Kovacs C, et al. Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol 2013; 191: 2164-2173.
63. Schuetz A, Deleage C, Sereti I, et al. PLOS pathogens: initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog 2014; 10: e1004543.
64. Micci L, Ryan ES, Fromentin R, et al. Interleukin-21 decreases residual inflammation and reduces the virus reservoir in ART-treated, SIV-infected rhesus macaques. J Clin Invest 2015. (In press).
65. Gianella S, Massanella M, Wertheim JO, Smith DM. The sordid affair between human herpesvirus and HIV. J Infect Dis 2015; 212: 845-852.
66. Modjarrad K, Vermund SH. Effect of treating co-infections on HIV-1 viral load: a systematic review. Lancet Infect Dis 2010; 10: 455-463.
67. McNally JM, Zarozinski CC, Lin MY, et al. Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses. J Virol 2001; 75: 5965-5976.
68. Gianella S, Strain MC, Rought SE, et al. Associations between virologic and immunologic dynamics in blood and in the male genital tract. J Virol 2012; 86: 1307-1315.
69. Gianella S, Anderson CM, Vargas MV, et al. Cytomegalovirus DNA in semen and blood is associated with higher levels of proviral HIV DNA. J Infect Dis 2013; 207: 898-902.
70. Gianella S, Massanella M, Richman DD, et al. Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment. J Virol 2014; 88: 7818-7827.
71. Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 2011; 203: 1474-1483.
72. Maldarelli F, Wu X, Su L, et al. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 2014; 345: 179-183.
73. Wagner TA, McLaughlin S, Garg K, et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 2014; 345: 570-573.
74. Cohn LB, Silva IT, Oliveira TY, et al. HIV-1 integration landscape during latent and active infection. Cell 2015; 160: 420-432.
75. Josefsson L, Stockenstrom von S, Faria NR, et al. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci 2013; 110: E4987-E4996.
76. Stockenstrom von S, Odevall L, Lee E, et al. Longitudinal genetic characterization reveals that cell proliferation maintains a persistent HIV type 1 DNA pool during effective HIV therapy. J Infect Dis 2015; 212: 596-607.
77. Massanella M, Gómez-Mora E, Carrillo J, et al. Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery. J Translat Med 2015; 13: 141.
78. Camargo JF, Kulkarni H, Agan BK, et al. Responsiveness of T cells to interleukin-7 is associated with higher CD4+ T cell counts in HIV-1-positive individuals with highly active antiretroviral therapy-induced viral load suppression. J Infect Dis 2009; 199: 1872-1882.
79. Vandergeeten C, Fromentin R, DaFonseca S, et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 2013; 121: 4321-4329.
80. Cockerham LR, Jain V, Sinclair E, et al. Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease. AIDS (London, England) 2014; 28: 1749-1758.
81. Kinter AL, Godbout EJ, McNally JP, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008; 181: 6738-6746.
82. Fromentin R, Bakeman W, Lawani MB, et al. The immune checkpoints PD-1, LAG-3 and TIGIT are biomarkers of HIV infected cells during ART and identify distinct cellular reservoirs. In: Towards an HIV cure Preconference Symposium; 2014; Sydney (Australia).
83. Yukl SA, Shergill AK, Girling V, et al. Site-specific differences in T cell frequencies and phenotypes in the blood and gut of HIV-uninfected and ARTtreated HIV+ adults. Plos One 2015; 10: e0121290.
84. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)- 2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203: 1693-1700.
85. Huang C-T, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity 2004; 21: 503-513.
86. Saison J, Ferry T, Demaret J, et al. Association between discordant immunological response to highly active antiretroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients. Clin Exp Immunol 2014; 176: 401-409.
87. Tran T-A, de Goë R de Herve M-G, Hendel-Chavez H, et al. Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy. Plos One 2008; 3: e3305.
88. Højen JF, Rasmussen TA, Andersen KLD, et al. Interleukin-37 expression is increased in chronic HIV-1-infected individuals and is associated with inflammation and the size of the total viral reservoir. Mol Med 2015; 21: 337-345.
89. Schmid A, Gianella S, Wyl von V, et al. Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. Plos One 2010; 5: e13310.
90. Pasternak AO, Adema KW, Bakker M, et al. Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol 2008; 46: 2206-2211.
91. Graf EH, Pace MJ, Peterson BA, et al. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected]. Plos One 2013; 8: e71879.
92. Mousseau G, Kessing CF, Fromentin R, et al. The Tat inhibitor didehydrocortistatin A prevents HIV-1 reactivation from latency. Bio 2015; 6: e00465.
93. Sandler NG, Sereti I. Can early therapy reduce inflammation? Curr Opin HIV AIDS 2014; 9: 72-79.
94. Stock PG, Barin B, Hatano H, et al., for Solid Organ Transplantation in HIV Study Investigators. Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients. Am J Transplant 2014; 14: 1136-1141.
95. Markowitz M, Vaida F, Hare CB, et al. The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis 2010; 201: 1298-1302.
96. Gavegnano C, Detorio M, Montero C, et al. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother 2014; 58: 1977-1986.
97. Olesen R, Vigano S, Rasmussen TA, et al. Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat. J Virol 2015; 89: 10176-10189.
98. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
99. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
100. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
101. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36: 491-501.
102. Wightman F, Solomon A, Kumar SS, et al. Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. AIDS (London, England) 2015; 29: 504-506.